Tatoo - Treat-to-Target in Inflammatory Bowel Disease
Research type
Research Study
Full title
Tatoo - Treat-to-Target and Disease Modification in Inflammatory Bowel Disease: A Worldwide Routine Practice Study.
IRAS ID
361827
Contact name
Sailish Honap
Contact email
Sponsor organisation
AbbVie
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
When managing patients with inflammatory bowel disease (IBD) such as Crohn’s Disease or Ulcerative Colitis, one of the options is to use a treat-to-target strategy (T2T). This means that doctors set specific goals for your treatment, like getting your symptoms under control or reducing inflammation in your gut and then adjust your medicine or care along the way to ensure you reach those goals.
Although many doctors agree T2T is important, in everyday life it cannot always be followed, for reasons such as differences between patients and the way doctors treat their patients, as well as limitations on healthcare time and resources. Also, there is no long-term evidence to show that this type of management results in better outcomes for patients.
The main aims of this study are to find out how T2T is being put into practice in real life around the world and to examine if following a T2T strategy leads to improvements in a patient’s disease.
The study will be open to adult patients aged 20 and older who have been diagnosed with either Crohn’s disease or ulcerative colitis for at least two years. Patients who have undergone certain types of bowel surgery or those using medication or a medical device as part of a clinical trial will not be eligible to take part.This study is an observational retrospective study which is a type of research where doctors look back at existing records or data about people who have already been treated in the past. No medical procedures are performed, and no changes are made to any patient’s treatment.
This study will review medical records from eligible patients, from the day they enrol in the study, looking back two years, to understand how IBD is managed in different countries.
REC name
South Central - Hampshire B Research Ethics Committee
REC reference
26/SC/0139
Date of REC Opinion
22 Jun 2026
REC opinion
Further Information Favourable Opinion